In NSCLC, NTRK gene fusions exhibit higher TMB and PD-L1 expression than EGFR, ALK, and ROS1 alterations, suggesting a combination of chemotherapy and immunotherapy for comprehensive treatment [93, 94]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.